TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p

Leukemia

Volumn 24, Issue 1, 2010, Pages 216-219

  Jasek, M ^a   Gondek, L P ^a   Bejanyan, N ^a   Tiu, R ^a   Huh, J ^a,b   Theil, K S ^c   O'Keefe, C ^a   McDevitt, M A ^d   MacIejewski, J P ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b Ewha Womans University School of Medicine   (South Korea)

^c LERNER RESEARCH INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; APLASTIC ANEMIA; CARCINOGENESIS; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CYTOGENETICS; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; KARYOTYPE; LETTER; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 74249120916     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.189     Document Type: Letter

References (8)

1. Maciejewski JP, Mufti GJ. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood 2008; 112: 965-974.
2. Lai JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Lepelley P et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 1995; 9: 370-381.
3. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-629.
4. Wilentz RE, Argani P, Hruban RH. Loss of heterozygosity or intragenic mutation, which comes first? Am J Pathol 2001; 158: 1561-1563.
5. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001; 19: 1405-1413.
6. Bowen D, Groves MJ, Burnett AK, Patel Y, Allen C, Green C et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia 2009; 23: 203-206.
7. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 2008; 22: 1539-1541.
8. Alvarez S, Cigudosa JC. Gains, losses and complex karyotypes in myeloid disorders: a light at the end of the tunnel. Hematol Oncol 2005; 23: 18-25.